Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389590 | 1.00 | TGFBR1 (0.41) | TGFBR1MAPK14KDRFGFR1FGFR3 | |
| SCHEMBL25084865 | 0.91 | FGFR1 (0.41) | TGFBR1KDRFGFR1FGFR3FLT3 | |
| SCHEMBL30156408 | 0.91 | FGFR1 (0.41) | TGFBR1KDRFGFR1FGFR3FLT3 | |
| SCHEMBL23392175 | 0.90 | TGFBR1 (0.45) | TGFBR1MAPK14KDRFGFR1FGFR3 | |
| SCHEMBL25085211 | 0.88 | TGFBR1 (0.40) | TGFBR1MAPK14KDRMETCYP1A2 | |
| SCHEMBL29796379 | 0.88 | TGFBR1 (0.42) | TGFBR1MAPK14KDRFGFR1FGFR3 | |
| SCHEMBL23389789 | 0.88 | TGFBR1 (0.42) | TGFBR1MAPK14KDRFGFR1FGFR3 | |
| SCHEMBL23391921 | 0.87 | TGFBR1 (0.42) | TGFBR1MAPK14KDRCYP1A2PDGFRA | |
| SCHEMBL30156049 | 0.86 | MET (0.40) | TGFBR1MAPK14KDRFGFR1FGFR3 | |
| SCHEMBL22075156 | 0.84 | MET (0.46) | TGFBR1MAPK14KDRFGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4061809-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MAPK14 1504/4885KDR 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.